Climb Bio (CLYM)

• Market cap: $132M
• 1 day: -6.15%
• 5 days: -10.73%
• 1 month: 10.91%
• 3 months: 8.93%
• 6 months: 51.24%
• Year to date: -11.59%
• 1 year: -48.01%
• 5 years: -88.49%
• 10 years: -88.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18